Journal of Clinical Endocrinology & Metabolism, Vol 81, 1031-1034, Copyright © 1996 by Endocrine Society

ARTICLES

Finasteride therapy does not alter bone turnover in men with benign prostatic hyperplasia--a Clinical Research Center study

SR Tollin, HN Rosen, K Zurowski, B Saltzman, AJ Zeind, S Berg and SL Greenspan
Charles A. Dana Research Institute, Boston, Massachusetts, USA.

Benign prostatic hyperplasia is often treated with finasteride, which inhibits the conversion of testosterone to dihydrotestosterone (DHT). Aside from the prostate, other androgen-dependent tissues seem to be unaffected by selective DHT deficiency, but the effect on bone density in humans has not yet been defined. To study this question, we compared indices of bone turnover and bone mineral density in 35 men treated with finasteride with controls. Bone resorption was assessed by measuring urinary excretion of N-telopeptide cross-links of type I collagen and hydroxyproline, and bone formation was assessed by measuring serum osteoncalcin and bone-specific alkaline phosphatase. Bone density of the spine and hip were assessed by dual energy x-ray absorptiometry. We found that finasteride-treated patients had mean DHT levels 81% lower than controls (P < 0.0001). There were no significant differences between the two groups in any of the markers of bone turnover or measures of bone density. These results suggest that testosterone can maintain bone density in men even in the absence of DHT. Although long term studies are needed, our results suggest that men who take finasteride are not at increased risk for bone loss.

This article has been cited by other articles:

				J. F. Yarrow, C. F. Conover, A. V. Purandare, A. M. Bhakta, N. Zheng, B. Conrad, M. K. Altman, S. E. Franz, T. J. Wronski, and S. E. Borst Supraphysiological testosterone enanthate administration prevents bone loss and augments bone strength in gonadectomized male and female rats Am J Physiol Endocrinol Metab, November 1, 2008; 295(5): E1213 - E1222. [Abstract] [Full Text] [PDF]

				S. J. Jacobsen, T. C. Cheetham, R. Haque, J. M. Shi, and R. K. Loo Association Between 5-{alpha} Reductase Inhibition and Risk of Hip Fracture JAMA, October 8, 2008; 300(14): 1660 - 1664. [Abstract] [Full Text] [PDF]

				H. J. Litman, S. Bhasin, C. L. Link, A. B. Araujo, J. B. McKinlay, and for the Boston Area Community Health Survey Invest Serum Androgen Levels in Black, Hispanic, and White Men J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4326 - 4334. [Abstract] [Full Text] [PDF]

				V Rochira, A Balestrieri, B Madeo, L Zirilli, A R M Granata, and C Carani Osteoporosis and male age-related hypogonadism: role of sex steroids on bone (patho)physiology Eur. J. Endocrinol., February 1, 2006; 154(2): 175 - 185. [Abstract] [Full Text] [PDF]

				D. Vanderschueren, L. Vandenput, S. Boonen, M. K. Lindberg, R. Bouillon, and C. Ohlsson Androgens and Bone Endocr. Rev., June 1, 2004; 25(3): 389 - 425. [Abstract] [Full Text] [PDF]

				J. K. Amory, N. B. Watts, K. A. Easley, P. R. Sutton, B. D. Anawalt, A. M. Matsumoto, W. J. Bremner, and J. L. Tenover Exogenous Testosterone or Testosterone with Finasteride Increases Bone Mineral Density in Older Men with Low Serum Testosterone J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 503 - 510. [Abstract] [Full Text] [PDF]

				J. Compston Local Biosynthesis of Sex Steroids in Bone J. Clin. Endocrinol. Metab., December 1, 2002; 87(12): 5398 - 5400. [Full Text] [PDF]

				S. Issa, D. Schnabel, M. Feix, L. Wolf, H.-E. Schaefer, D. W. Russell, and H.-U. Schweikert Human Osteoblast-Like Cells Express Predominantly Steroid 5{alpha}-Reductase Type 1 J. Clin. Endocrinol. Metab., December 1, 2002; 87(12): 5401 - 5407. [Abstract] [Full Text] [PDF]